Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Rating Lowered by Wall Street Zen

Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

A number of other equities analysts also recently commented on the stock. Stifel Nicolaus set a $275.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, August 4th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Jazz Pharmaceuticals in a report on Tuesday, June 9th. Royal Bank Of Canada set a $299.00 price target on Jazz Pharmaceuticals in a report on Friday, August 28th. Bank of America raised their price objective on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Finally, JPMorgan Chase & Co. boosted their price objective on Jazz Pharmaceuticals from $265.00 to $276.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $291.15.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $235.67 on Friday. The business’s 50-day simple moving average is $247.07 and its 200-day simple moving average is $229.70. The firm has a market capitalization of $15.30 billion, a P/E ratio of 16.25, a P/E/G ratio of 0.21 and a beta of 0.37. Jazz Pharmaceuticals has a 1-year low of $128.80 and a 1-year high of $266.38. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.78 and a quick ratio of 1.58.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.18 by ($0.47). The business had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.11 billion. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The company’s quarterly revenue was up 15.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($8.25) EPS. Equities analysts predict that Jazz Pharmaceuticals will post 21.61 EPS for the current year.

Insider Activity

In related news, CEO Renée Galá sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $243.03, for a total transaction of $486,060.00. Following the sale, the chief executive officer owned 143,394 shares of the company’s stock, valued at $34,849,043.82. The trade was a 1.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce Cozadd sold 6,000 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $252.98, for a total transaction of $1,517,880.00. Following the completion of the transaction, the director owned 360,682 shares in the company, valued at $91,245,332.36. This represents a 1.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 92,121 shares of company stock valued at $23,001,022 over the last ninety days. 4.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of JAZZ. USA Financial Formulas acquired a new stake in Jazz Pharmaceuticals during the 1st quarter valued at approximately $25,000. Ameritas Advisory Services LLC acquired a new position in shares of Jazz Pharmaceuticals in the 2nd quarter valued at approximately $47,000. Westpac Banking Corp acquired a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at approximately $51,000. Root Financial Partners LLC boosted its stake in shares of Jazz Pharmaceuticals by 42.8% during the 1st quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock valued at $56,000 after buying an additional 89 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at approximately $61,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious neurological and oncology-related conditions. Founded in 2003 and headquartered in Dublin, Ireland, the company operates internationally, with a significant commercial presence in the United States and other markets.

Jazz’s neuroscience portfolio includes Xywav and Xyrem, which contain oxybate and are used to treat narcolepsy-related symptoms; Xywav is also approved for idiopathic hypersomnia in adults.